Widespread use of pertussis vaccines in children has resulted in a >90% reduction in the number of annual pertussis cases in the United States. After a period of low U.S. pertussis incidence during and shortly after the COVID-19 pandemic, incidence increased in 2024. Data on the real-world effectiveness of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) against pertussis during this disease resurgence are limited. In response to documentation of a record high pertussis incidence in Alaska during May-November 2024, DTaP vaccine effectiveness (VE) against pertussis in Alaska children aged 6 months-6 years was evaluated. Adjusted VE was 96.2% among children who had completed the 3-dose primary DTaP series and 85.3% among those who were partially vaccinated. Compared with children who had received ≥3 DTaP doses, the odds of laboratory-confirmed pertussis were approximately 26 times as high in unvaccinated children (adjusted odds ratio [OR] = 26.1), and approximately 4 times as high in those who had received 1-2 DTaP doses (adjusted OR = 3.8). These findings reinforce the importance of following pertussis vaccination recommendations to protect for children from the disease and reduce the occurrence of pertussis outbreaks.
No takes yet. Share an insight, caveat, or question.
Newell et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: